Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Open Label Study to Assess the Safety and Tolerability of VM202 in Subjects With Amyotrophic Lateral Sclerosis

Trial Profile

A Phase I/II, Open Label Study to Assess the Safety and Tolerability of VM202 in Subjects With Amyotrophic Lateral Sclerosis

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Donaperminogene seltoplasmid (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Sponsors Helixmith; ViroMed
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 09 Feb 2017 According to VM BioPharma media release, clinical safety and tolerability data was published online at the scientific journal, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration and will be published in a future print issue of the journal.
    • 17 May 2016 According to a ViroMed media release, the US FDA granted fast track designation to VM202 for the potential treatment of ALS. ViroMed expects the publication of data from this trial in H2 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top